Is HCW Biologics Stock a Good Investment?
HCW Biologics Investment Advice | HCWB |
- Examine HCW Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research HCW Biologics' leadership team and their track record. Good management can help HCW Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact HCW Biologics' business and its evolving consumer preferences.
- Compare HCW Biologics' performance and market position to its competitors. Analyze how HCW Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if HCW Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about HCW Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in HCW Biologics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if HCW Biologics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine HCW Biologics Stock
Researching HCW Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 52.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.05. HCW Biologics had not issued any dividends in recent years.
To determine if HCW Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding HCW Biologics' research are outlined below:
| HCW Biologics is way too risky over 90 days horizon | |
| HCW Biologics has some characteristics of a very speculative penny stock | |
| HCW Biologics appears to be risky and price may revert if volatility continues | |
| HCW Biologics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.84 M. Net Loss for the year was (24.99 M) with profit before overhead, payroll, taxes, and interest of 4.1 M. | |
| HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 52.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Byam Rebecca of 20000 shares of HCW Biologics at 1.6598 subject to Rule 16b-3 |
HCW Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in HCW Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to HCW Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact HCW Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises HCW Biologics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-12 | 2022-06-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2023-08-11 | 2023-06-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2022-05-13 | 2022-03-31 | -0.11 | -0.06 | 0.05 | 45 | ||
2022-03-29 | 2021-12-31 | -0.12 | -0.17 | -0.05 | 41 | ||
2024-03-26 | 2023-12-31 | -0.145 | -0.3 | -0.155 | 106 | ||
2024-05-15 | 2024-03-31 | -0.14 | -0.3 | -0.16 | 114 |
Know HCW Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as HCW Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading HCW Biologics backward and forwards among themselves. HCW Biologics' institutional investor refers to the entity that pools money to purchase HCW Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2024-12-31 | 15.6 K | Renaissance Technologies Corp | 2024-12-31 | 15 K | Two Sigma Investments Llc | 2024-12-31 | 12.1 K | Northern Trust Corp | 2024-12-31 | 10.2 K | Tower Research Capital Llc | 2024-12-31 | 1.8 K | Bank Of America Corp | 2024-12-31 | 146 | Jane Street Group Llc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 2 M | Honkamp Krueger Financial Services Inc | 2024-12-31 | 279.5 K |
HCW Biologics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.95 M.Market Cap |
|
HCW Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.01) | (1.06) | |
| Return On Capital Employed | (1.50) | (1.42) | |
| Return On Assets | (1.01) | (1.06) | |
| Return On Equity | (2.14) | (2.03) |
Determining HCW Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if HCW Biologics is a good buy. For example, gross profit margin measures HCW Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of HCW Biologics' profitability and make more informed investment decisions.
Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.
Evaluate HCW Biologics' management efficiency
HCW Biologics has return on total asset (ROA) of (0.7009) % which means that it has lost $0.7009 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4432) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -1.06. The current year's Return On Capital Employed is expected to grow to -1.42. At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 61.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.34 | 0.56 | |
| Tangible Book Value Per Share | 0.34 | 0.56 | |
| Enterprise Value Over EBITDA | (1.79) | (1.88) | |
| Price Book Value Ratio | 3.78 | 3.59 | |
| Enterprise Value Multiple | (1.79) | (1.88) | |
| Price Fair Value | 3.78 | 3.59 | |
| Enterprise Value | 53.9 M | 62.6 M |
Effective management at HCW Biologics has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta 0.838 |
Basic technical analysis of HCW Stock
As of the 26th of February, HCW Biologics retains the market risk adjusted performance of 0.3473, and Coefficient Of Variation of (2,288). HCW Biologics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the entity's future prices.HCW Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific HCW Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on HCW Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases HCW Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
HCW Biologics' Outstanding Corporate Bonds
HCW Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. HCW Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most HCW bonds can be classified according to their maturity, which is the date when HCW Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC HLDGS PLC Corp BondUS404280AF65 | View | |
| HSBC HLDGS PLC Corp BondUS404280AG49 | View | |
| HSBC HLDGS PLC Corp BondUS404280AM17 | View | |
| HSBC HLDGS PLC Corp BondUS404280AH22 | View | |
| HSBC HLDGS PLC Corp BondUS404280AJ87 | View | |
| HSBC 6375 Corp BondUS404280AT69 | View | |
| HSBC HLDGS PLC Corp BondUS404280AU33 | View | |
| HSBC HLDGS PLC Corp BondUS404280AW98 | View |
Understand HCW Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing HCW Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.3473 | |||
| Mean Deviation | 7.73 | |||
| Coefficient Of Variation | (2,288) | |||
| Standard Deviation | 18.09 | |||
| Variance | 327.19 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.79) | |||
| Total Risk Alpha | (0.92) | |||
| Treynor Ratio | 0.3373 | |||
| Maximum Drawdown | 148.94 | |||
| Value At Risk | (18.75) | |||
| Potential Upside | 9.76 | |||
| Skewness | 5.73 | |||
| Kurtosis | 41.22 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.3473 | |||
| Mean Deviation | 7.73 | |||
| Coefficient Of Variation | (2,288) | |||
| Standard Deviation | 18.09 | |||
| Variance | 327.19 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.79) | |||
| Total Risk Alpha | (0.92) | |||
| Treynor Ratio | 0.3373 | |||
| Maximum Drawdown | 148.94 | |||
| Value At Risk | (18.75) | |||
| Potential Upside | 9.76 | |||
| Skewness | 5.73 | |||
| Kurtosis | 41.22 |
Consider HCW Biologics' intraday indicators
HCW Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of HCW Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 12295.89 | |||
| Daily Balance Of Power | (0.67) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.37 | |||
| Day Typical Price | 0.36 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 47.02 |
HCW Stock media impact
Far too much social signal, news, headlines, and media speculation about HCW Biologics that are available to investors today. That information is available publicly through HCW media outlets and privately through word of mouth or via HCW internal channels. However, regardless of the origin, that massive amount of HCW data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of HCW Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of HCW Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to HCW Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive HCW Biologics alpha.
HCW Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards HCW Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
HCW Biologics Corporate Management
| Hing Wong | CEO, Founder | Profile | |
| Lee Flowers | Senior Development | Profile | |
| Peter Rhode | Chief Operations | Profile | |
| Nicole Esq | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between HCW Biologics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.